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Abstract
Rationale Patients with obsessive-compulsive disorder (OCD) have been found to show exaggerated error responses and pre-
diction error learning signals in a variety of EEG and fMRI tasks, with data converging on the anterior cingulate cortex as a key
locus of dysfunction. Considerable evidence has linked prediction error processing to dopaminergic function.
Objective In this study, we investigate potential dopaminergic dysfunction during reward processing in the context of OCD.
Methods We studied OCD patients (n = 18) and controls (n = 18) whilst they learned probabilistic associations between abstract
stimuli and monetary rewards in the fMRI scanner involving administration (on separate visits) of a dopamine receptor agonist,
pramipexole 0.5 mg; a dopamine receptor antagonist, amisulpride 400mg; and placebo.We fitted a Q-learning computational model
to fMRI prediction error responses; group differences were examined in anterior cingulate and nucleus accumbens regions of interest.
Results There were no significant group, drug, or interaction effects in the number of correct choices; computational modeling
suggested a marginally significant difference in learning rates between groups (p = 0.089, partial ƞ2 = 0.1). In the imaging results,
there was a significant interaction of group by drug (p = 0.013, partial ƞ2 = 0.13). OCD patients showed abnormally strong
cingulate signaling of prediction errors during omission of an expected reward, with unexpected reduction by both pramipexole
and amisulpride (p = 0.014, partial ƞ2 = 0.26, 1-β error probability = 0.94). Exaggerated cingulate prediction error signaling to
omitted reward in placebo was related to trait subjective difficulty in self-regulating behavior in OCD.
Conclusions Our data support cingulate dysfunction during reward processing in OCD, and bidirectional remediation by dopami-
nergic modulation, suggesting that exaggerated cingulate error signals in OCD may be of dopaminergic origin. The results help to
illuminate the mechanisms through which dopamine receptor antagonists achieve therapeutic benefit in OCD. Further research is
needed to disentangle the different functions of dopamine receptor agonists and antagonists during bidirectional modulation of
cingulate activation.
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Introduction
Obsessive-compulsive disorder (OCD) has been associated
with deficits in learning and decision making (Gillan and
Robbins 2014; Nielen et al. 2009). OCD patients were found
to show reduced response control in punishment trials, with
impulsivity being correlated with severity of symptoms
(Morein-Zamir et al. 2013), and abnormal error responses in
a variety of response conflict and error monitoring tasks using
EEG (Gillan et al. 2017; Mathews et al. 2012), suggesting
overactivity of the performance monitoring system involving
the anterior cingulate cortex (Hammer et al. 2009).
Neural mechanisms underlying decision making and learn-
ing involve fronto-striatal networks generating reward predic-
tion errors which are highly sensitive to dopaminergic modu-
lation (Frank et al. 2004; Kehagia et al. 2010; Schultz and
Dickinson 2000). Extensive evidence from studies in experi-
mental animals has demonstrated that dopamine neurons
show increased rates of firing to unexpected or better than
expected rewards (positive prediction error), and a reduction
in firing rate during omission of expected rewards (negative
prediction error) (Schultz et al. 1997). Studies in healthy hu-
man volunteers have shown dopaminergic modulation of the
brain response to a reward prediction error response using
fMRI (Bernacer et al. 2013; Eisenegger et al. 2014;
Pessiglione et al. 2006). Evidence from human molecular im-
aging studies of patients with OCD suggests a possible role for
dopaminergic pathology in OCD (Denys et al. 2004; Hesse
et al. 2005; Moresco et al. 2007; Olver et al. 2009, 2010;
Perani et al. 2008; Sesia et al. 2013; Van Der Wee et al.
2004). Whilst dopaminergic medications are not first-line
treatments for OCD, dopamine receptor antagonists are often
used to augment first-line treatment in refractory cases
(Hirschtritt et al. 2017) and the efficacy of this strategy is
confirmed by meta-analyses (Dold et al. 2015; Veale et al.
2014).
Notably, the nucleus accumbens (part of the ventral stria-
tum) receives dense dopaminergic projections and is a target
for deep brain stimulation in OCD (Denys et al. 2010). A prior
study demonstrated abnormal reward processing in the nucle-
us accumbens in OCD (Figee et al. 2011): it reported attenu-
ated activations for reward anticipation but did not examine
learning or prediction error signaling. The nucleus accumbens
has notably been associated with coding prediction error in
healthy controls (Abler et al. 2006; O’doherty et al. 2004;
Pagnoni et al. 2002; Rodriguez et al. 2006). The concept of
negative prediction error is closely related to that of error
monitoring, which is reliably abnormal in OCD, although
the two processes are not identical. Both processes involve
evaluatingworse than expected outcome,motivating the study
of prediction error signaling in OCD. Recently, Hauser et al.
(2017) reported increased brain signals in response to reward
prediction errors in the anterior cingulate cortex and the
putamen, indicating an overactivation of the monitoring sys-
tem. Furthermore, dopamine-dependent activation in the an-
terior cingulate has also been associated with increased error
awareness and performance monitoring (Hester et al. 2012;
Pauls et al. 2012). Reward prediction error processing is close-
ly linked to the dopaminergic system (Schultz et al. 1997). A
plausible hypothesis unifying (I) the known role of dopamine
in signaling reward prediction errors, (II) the existing evidence
of dopaminergic pathology in OCD, and (III) evidence of
abnormal error processing in OCD is that OCD patients may
exhibit abnormal processing of reward prediction errors, es-
pecially during omission of expected reward linked to abnor-
mal dopaminergic function.
To our knowledge, no study has yet examined a direct
modulation of the dopaminergic system on a reward predic-
tion error task in OCD. In the current experiment, we therefore
compared the effect of dopaminergic drug treatments on pre-
diction error signaling in OCD. We recruited a group of pa-
tients with OCD and a group of healthy volunteers as controls,
and examined brain responses during studies of reinforcement
learning in an fMRI scanner after administration of a dopa-
mine D2/3 receptor agonist, pramipexole, or a dopamine D2/3
receptor antagonist, amisulpride, or a placebo. We hypothe-
sized that fronto-striatal reward prediction error signaling in
OCD would be exaggerated under placebo; given the evi-
dence for dopamine receptor antagonism add-on treatment
for OCD, we hypothesized that this abnormality would be
normalized by amisulpride but not by pramipexole, which
has been shown in some cases to worsen compulsivity
(Kolla et al. 2010). Our hypotheses were principally focused
on two brain regions of particular interest: we predicted that
dopaminergic abnormalities in anterior cingulate reward pre-
diction errors would be prominent in OCD during processing
of omitted rewards, as this is analogous to the enhanced cin-
gulate error signaling suggested by error-related negativity
studies in OCD (Gillan et al. 2017). A secondary hypothesis
was that, in the nucleus accumbens (Figee et al. 2011), there
would be dopaminergic reward prediction error abnormalities
in OCD (during reward receipt and/or omission).
Methods
Participants
Thirty-six right-handed volunteers participated in this study
(Table 1): 18 individuals satisfying DSM-IV-TR criteria for
OCD, and 18 healthy controls. The groups were matched for
age, gender, IQ, and years of education. Prior to study enroll-
ment, all participants had a satisfactory medical review and
were screened for any other current Axis I psychiatric disorder
using the Structured Clinical Interview for the DSM-IV-TR
Axis I psychiatric disorders. OCD patients were recruited
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from a specialist OCD clinic and through independent chari-
ties, and most were taking serotonin selective reuptake inhib-
itor (SSRI) medication (see Supplementary Material for
details). Participants were excluded based on any other Axis
I psychiatric disorders. All volunteers provided written in-
formed consent. The study was approved by the Cambridge
Research Ethics Committee.
Pharmacological interventions
Participants attended for three in-unit assessments in which
treatments were administered by mouth. On one visit, they
received 0.5 mg pramipexole, a selective agonist at the dopa-
mine D2/3 receptors; on another visit, 400 mg amisulpride, a
selective antagonist at the dopamine D2/3 receptors, and on
another visit, a placebo. Drug administration was conducted
in a double-blind, placebo-controlled fashion counterbalanced
for drug/visit order. Each dosing of drug/placebo was admin-
istrated 60 min prior to scanning to assure peak plasma levels
for both drugs during scanning. The time point of drug admin-
istration was based on pharmacokinetic data for both drugs
(Coukell et al. 1996; Rosenzweig et al. 2002; Wright et al.
1997).
Patients’ eligibility to proceed with the scanning was as-
sured by ECG monitoring. We initially administered a single
oral dose of 1.5 mg of pramipexole to the first three healthy
volunteers. However, this dose of pramipexole was poorly
tolerated; the three healthy volunteers were unable to perform
the tasks at this treatment session because of nausea, vomiting,
sweating, and tiredness. Subsequently, the dose of
pramipexole was reduced to 0.5 mg orally for all participants
(i.e., for 18 controls, including the three volunteers who did
not tolerate the higher dose). All participants were also admin-
istered a total of 30 mg of domperidone orally for each
treatment session to prevent emetic effects of dopamine
receptor agonism. The administration was split up over
three time points. Ten milligrams of domperidone was
to be taken 12 h and 2 h before arrival, and further
10 mg of domperidone was administered together with the
study medication.
Subjective drug effects were assessed at two time points, 1
and 1.5 h after drug administration using the Bond-Lader
Visual Analogue Scale (BOND and LADER 1974). The time
points referred to assessment immediately before and after
fMRI scanning. At this time points, blood samples were taken
from the participants, to assess plasma-levels and prolactin
concentration.
fMRI task
During the fMRI scan, subjects carried out a probabilistic
learning task that required making choices to maximize wins
and minimize losses (Fig. 1), adapted from previous similar
tasks (Bernacer et al. 2013; Ermakova et al. 2018; O’doherty
et al. 2004; Pessiglione et al. 2006). In each trial, one of three
possible pairs of abstract pictures was randomly presented:
rewarding, punishing, or neutral (40 trials of each valence).
For each trial, the subject used a button push to indicate a
choice of picture. When viewing the potentially rewarding
pair, selection of one of the pictures led to a financial win with
a 70% probability and of a no-change outcome with 30%
probability, whereas the selection of the other picture led to
gain with only 30% probability. The potentially punishing pair
led to a financial loss on 70% and 30% trials depending on
stimulus choice, and the neutral pair led to no change. We
focus in this report on how participants learned about rewards;
hence, we report fMRI results from the reward trials only.
Details of behavior on other trial types are reported in the
Supplementary Material.
Behavioral analysis
We used a repeated measures analysis of variance (ANOVA)
to investigate the group differences (controls, OCD; between
subjects’ variable) and effect of drug (placebo, pramipexole,
amisulpride; within subjects’ variable) in stimuli choices and
reaction times. We were interested in the proportion with
which the subjects gave a Bcorrect^ response and whether this
performance was dependent on trial types and drugs. Stimulus
selection was considered correct when choosing the stimulus
with the high probability of leading to winning of 50 pence in
the reward trial (regardless of whether or not the partic-
ipant was rewarded on that particular trial), the picture
with the high probability of receiving a neutral feedback
picture in neutral trials, and stimulus with the high
probability of leading to no punishment. In the neutral
trials, the assignment of Bcorrectness^ is arbitrary but
assigning one stimulus in each category to be the correct stim-
ulus allows examination of to what extent response patterns
differed across trial types.
Computational learning model parameters (see below)
were analyzed in a repeated measures ANOVA with group
as a between-subjects’ variable and drug as a within-subjects’
variable.
Computational modeling of learning
We estimated the positive and negative reward prediction error
value for each trial, based on a basic Q learning algorithm
(Murray et al. 2008; Pessiglione et al. 2006), that involves
modeling learning rates (alpha) and Bexploration-
exploitation^ parameters (betas). Beta, also understood as
the inverse temperature, balances between random sampling
or exploration of actions, and the exploitation of current
knowledge (see the Supplementary Material for the detailed
description of the computational modeling methods).
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MRI analysis
MRI acquisition is described in the Supplementary Material.
Data were initially analyzed a voxelwise fashion using FSL
software (Jenkinson et al. 2012). Data were analyzed using the
FSL tool, FEAT (FMRI Expert Analysis Tool), using the fol-
lowing steps. EPI images were realigned, motion corrected, and
spatially smoothed with a Gaussian kernel of 6 mm (full-width
half-maximum). The time series in each session was high-pass
filtered (60 s cut-off), and the images were registered to the
structural MPRAGE scan obtained from the corresponding sub-
ject (having first removed the skull using the brain extraction
tool BET) and finally transformed into standard space using the
MNI template.
In the analysis of fMRI data, eight explanatory variables
(EVs), along with their temporal derivatives (used instead of
slice timing correction), were defined in our model as follows:
(1) reward expected value; (2) positive reward prediction error;
(3) negative reward prediction error; (4) punishment expected
value; (5) positive punishment PE; (6) negative punishment PE;
(7) feedback presentation; (8) cue presentation. FSL requires all
events to be set with non-zero duration: we set all to be 2 s. EVs
1–6 were based on the trial by trial computational model esti-
mates of reward cue values and prediction errors. The timings
of EVs1 and 4 correspond to cue presentation. EVs 2, 3, 5 and 6
correspond to the times of delivery of reward or omission of
expected reward. EV2 represents reward prediction error when
a reward is received (i.e., positive prediction error), and EV3
represents the prediction error when an expected reward is
omitted (negative prediction error). A positive EV3 parameter
estimate, therefore, reflects lower BOLD values during omis-
sion of predicted rewards. Positive and negative reward predic-
tion error activity were considered separately, as prior research
in OCD has focused on brain correlates of errors using tasks
where an error is usually accompanied by negative feedback or
represents some kind of mistake, which is more analogous to
negative prediction error than positive prediction error. In the
present analysis, we focused on EV2 and EV3, the positive and
negative reward prediction errors. We computed separate + 1
contrasts on EV2, and on EV3 at the single subject level (con-
trast of parameter estimates, or COPEs). We defined two re-
gions of interest (ROIs: see below and Supplementary
Material) and extracted average COPE values from each par-
ticipant in these ROIs, in order to subject these to ANOVA in
the statistics package SPSS. Before ANOVA was performed,
we examined the distributions of the COPE values and exclud-
ed outliers more than three standard deviations away from the
mean of all the samples pooled (Howell 2009). Although, psy-
chologically, punishment learning is of considerable interest in
OCD, the neurochemical basis of punishment prediction error
signals is much less clear than those of reward prediction errors,
with prior studies (Pessiglione et al. 2006) failing to find evi-
dence of dopaminergic modulation of punishment prediction
error learning signals. For this reason, although our paradigm
included punishment learning, we did not proceed to formulate
or test hypotheses regarding punishment brain signals.
In this study, we were interested in the anterior cingulate
cortex, using a sphere, 14mm, centered at x = 0, y = 42, z = 18,
based on (Hauser et al. 2017), and the nucleus accumbens, as
defined as in the Harvard-Oxford-subcortical atlas supplied
with FSL, during prediction error processing.
Relation to behavioral scales
We determined relationships between anterior cingulate and
accumbens prediction error COPE values in placebo and be-
havioral scales using nonparametric correlations (Spearman’s
rho). We examined total OCD symptoms (in patients only) as
Table 1 Subject characteristics.
Mean scores (SD) are shown for
continuously distributed variables
according to diagnostic group
Statistical results
Controls OCD t df p
Age (years) 32.1 (6.5) 35.6 (10.1) 0.95 34 0.35
Gender (male:female) 15:3 11:7 1.49 34 0.15
Height (cm) 177.0 (9.1) 170.4 (8.3) 2.25 33 0.03
Weight (kg) 79.2 (12.6) 80.4 (12.7) 0.26 32 0.80
BMI 25.1 (2.9) 27.8 (0.6) 1.97 32 0.06
Verbal IQ (NART) 108.2 (6.1) 107.8 (9.2) 0.22 34 0.83
Years of education 12.5 (1.8) 12.4 (2.1) 0.26 34 0.80
Self-regulation scale (SRQ total score at baseline)
Searching for options
Implementing a plan
Triggering change
225.7 (16.2)
31.9 (4.0)
34.7 (3.0)
31.1 (2.1)
199.9 (21.6)
29.7 (5.0)
26.9 (5.1)
28.5 (3.1)
4.02
1.43
5.56
2.92
33
33
33
33
< 0.001
0.17
< 0.001
0.006
Age of onset (years) of OCD) – 17.8 (10.9)
Severity of OCD (Y-BOCS score at baseline) 24.1 (6.8)
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measured by the Y-BOCS scale (Goodman et al. 1989) and a
subjective assessment of goal-directed behavior/cognitive
control (in both groups) using the self-regulation question-
naire (SRQ), which assesses the trait ability to develop, im-
plement, and flexibly maintain planned behavior in order to
achieve one’s goals (Brown et al. 1999). It contains items for
receiving relevant information, evaluation, triggering change,
searching for option, formulating a plan, implementing a plan,
and assessing effectiveness.
Results
Discrimination learning
Independent of drug, participants learned to choose the picture
that most often led to winning 50p (high-probability stimulus:
correct response) in the majority of reward trials (mean per-
centage of correct choices for controls 83.58% (± 26.3) and
patients 72.45% (± 34.9)); there was a tendency for OCD pa-
tients to make more errors across all treatment conditions
(Fig. 2) (marginal effect: F = 3.5, dfn = 1, dfe = 34, p =
0.070, partial ƞ2 = 0.09), but no effect of drug (p = 0.39) or
group X drug interaction (p = 0.86). (See Supplementary
Material for learning curves for reward trials, and description
of other trial types.)
Reaction time results
There was a significant main effect of drug (F = 5.63, dfn = 2,
dfe = 68, p = 0.005, partial ƞ2 = 0.14), but no effect of group
(p = 0.62) or an interaction (p = 0.70). Bonferroni corrected
post hoc tests revealed that participants independently of
group reacted to the reward trials significantly slower under
Fig. 1 Panel a presents the three different trial types and feedback
probabilities. Panel b presents the experimental task, including trial
timing. With cue presentation, participants have a maximum of 2 s to
make a decision. The chosen stimulus is circled in red and presented for
3 s. Feedback or no feedback is presented for 1 s, which is followed by a
fixation cross for a minimum of 0.5 s (0.5 s + (2 s—reaction time))
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pramipexole (845.29 ms ± 29.22) compared with placebo
(770.93 ms ± 23.66; p = 0.016), or amisulpride (757.86 ms ±
26.41; p = 0.002) (see Supplementary Material Results and
Table 1 for more details).
Computational modeling parameters
For the learning rate, α, we found a marginal effect of group
(F = 3.07, dfn = 1, dfe = 34, p = 0.089, partial ƞ2 = 0.1), but no
effect of drug (p = 0.94) or an interaction (p = 0.31). The mar-
ginally significant group effect suggests that controls, inde-
pendent of drug, have a higher learning rate (mean α = 0.27,
standard error 0.02) than OCD patients (mean α = 0.22, stan-
dard error 0.02). For β, there were no differences across
groups (p = 0.82), drug (p = 0.1) or an interaction (p = 0.78).
There was no effect of drug (p = 0.38), group (p = 0.22), or
interaction (p = 0.54) on model fit.
Imaging results, pooled data (Bmain effect of task^)
Results from pooled data, collapsing over group and drug
conditions, are presented in Supplementary Material.
Imaging results: anterior cingulate cortex, negative
prediction error
The mean COPE values for negative prediction error in the
anterior cingulate cortex were extracted to enable a region of
interest analysis in accordance with our hypothesis. Data from
three OCD patients were excluded because, for at least one of
the sessions, the mean COPE value from the ROI was over
three standard deviations from the mean of the entire sample.
Following repeated measure ANOVA, there were no main
effects of group (p = 0.88) or drug (p = 0.44). However, there
was a significant interaction of group by drug (F = 4.65, dfn =
1,2, dfe = 30,62, p = 0.013, partial ƞ2 = 0.13, 1-β error proba-
bility = 0.7). Within each group, we then conducted a
Bonferroni corrected post hoc test analyzing the effect of the
drug with a repeated measures ANOVA. In controls, the drug
intervention did not influence negative reward prediction error
processing, as shown by a non-significant drug effect (p =
0.16). In the OCD patients, however, there was a significant
drug effect (F = 5.01, dfn = 2, dfe = 28, p = 0.014, partial ƞ2 =
0.26, 1-β error probability = 0.94). On further analysis within
the patient group, amisulpride (mean = − 40.03, SD = 157.35)
as well as pramipexole (mean = − 20.83, SD = 133.09) led to
significant differences compared with placebo but not be-
tween themselves (mean = 128.56, SD = 189.54): placebo >
amisulpride, p = 0.030; placebo > pramipexole, p = 0.017;
amisulpride > pramipexole, p = 0.70.
Furthermore, we applied a univariate ANOVA to each drug
intervention separately (Fig. 3). For placebo, there was a sig-
nificant effect for group (F = 8.84, dfn = 1, dfe = 31, p =
0.006, partial ƞ2 = 0.22, 1-β error probability = 0.91), showing
that the COPE values in the controls (mean = − 42.21, SD =
140.24) were lower than in OCD (mean = 128.57, SD =
189.54). For the other two interventions, no significant differ-
ences were found between groups (amisulpride: controls
(mean = 15.12, SD = 243.59) > OCD (mean = − 40.03, SD =
157.35), p = 0.46; pramipexole: controls (mean = 117.4, SD =
362.97) > OCD (mean = − 20.83, SD = 133.09), p = 0.17).
Imaging results: anterior cingulate cortex, positive
prediction error
There were no significant group, drug, or interaction effects
for positive prediction error in the anterior cingulate cortex in
a repeated measure ANOVA.
Imaging results: nucleus accumbens, negative
prediction error
There were no significant group or drug or interaction effects
on negative prediction error COPE values in the nucleus
accumbens.
Imaging results: nucleus accumbens, positive
prediction error
The mean COPE values for positive prediction error in the
nucleus accumbens were extracted to enable a region of inter-
est analysis in accordance with our hypothesis. Data from
three controls and one OCD patient were excluded as, on at
least one of the different treatment sessions, the mean COPE
values from the ROI were over three standard deviations from
the mean of the entire sample. Following repeated measure
ANOVA, there was a significant main effect of group (F =
11.82, dfn = 1, dfe = 30, p = 0.002, partial ƞ2 = 0.28, 1-β error
probability = 0.96), but no significant effect for drug (p =
0.45) or interaction of group by drug (p = 0.54).
Fig. 2 Choice performance (mean ± 1 SEM) during reward trials under
different drugs, separated by group
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We then applied a univariate ANOVA to each drug inter-
vention separately (Fig. 4). For placebo, there was a signifi-
cant effect for group (F = 5.11, dfn = 1, dfe = 30 p = 0.031,
partial ƞ2 = 0.15, 1-β error probability = 0.75), showing that
the COPE values in the controls (mean = 32.28, SD = 120.46)
were significantly less than in the OCD group (mean =
125.74, SD = 113.32). For the amisulpride intervention, no
significant differences were found between groups
(amisulpride: controls (mean = 89.15, SD = 125.77) > OCD
(mean = 110.81, SD = 122.66); p = 0.63). For the pramipexole
intervention, we found a marginal effect (F = 2.90, dfn = 1,
dfe = 30, p = 0.099, partial ƞ2 = 0.09) with controls (mean =
23.36, SD = 124.58) showing less activity compared with
OCD patients (mean = 93.21, SD = 107.35).
We also conducted a Bonferroni corrected post hoc test
analyzing the effect of the drug within each group using re-
peated measure ANOVA. Neither in controls nor in OCD
patients did the drug intervention influence reward positive
prediction error processing (controls: p = 0.99; OCD patients:
p = 0.60).
SSRI treatment–medication interaction
In order to control for a potential interaction of the patients’
individual routine medication and the study drug treatment on
reward prediction error signaling, we created a dichotomized
medication variable (high dose or not high dose, the latter in-
cluding two medication-free patients) and used this variable as
a between-subject factor in a repeated measure ANOVA on the
three treatment types (i.e., placebo, pramipexole, amisulpiride).
We found a significant treatment effect on anterior cingulate
cortex negative prediction error COPE values (F = 5.42, dfd =
2, dfe = 6, p = 0.011), as in our analysis above without the
medication factor, but no SSRI medication dose effect (p =
0.8) or interaction (p = 0.3). In the nucleus accumbens, we did
not find any significant effect of high SSRI dose or interaction
on positive prediction error COPE values (all p > 0.1).
Correlations with behavioral scales
There was no correlation between placebo cingulate negative
prediction error COPE values and OCD symptoms as mea-
sured by Y-BOCS score (rho = − 0.2, p = 0.4). However, there
was a significant negative correlation between the cingulate
negative prediction error signal and trait self-regulation as
measured by the SRQ (rho = − 0.7, p = 0.002, including out-
liers; rho = − 0.75, p = 0.002, excluding outliers), such that
patients who reported more difficulty with self-regulation also
demonstrated exaggerated negative error signals in the anteri-
or cingulate (Fig. 5). On analyses of subscales, the overall
association was mainly driven by associations with subscales
for Btriggering change,^ Bsearching for options,^ and
Bimplementing a plan^ (all p < 0.005).
There were no correlations between placebo COPE values
in the nucleus accumbens and rating scales (Y-BOCS, self-
regulation including subscales, all p > 0.5).
Discussion
In this pharmacological fMRI study of reinforcement learning,
we found that OCD patients exhibited abnormally increased
signaling of prediction errors to omitted rewards in the ante-
rior cingulate cortex under placebo treatment, which was re-
duced by acute dopaminergic drug treatment using either
pramipexole or amisulpride. This bidirectional reduction was
unexpected and requires further analysis in future research.
Furthermore, we found that OCD patients also showed abnor-
mally increased activity associated with positive prediction
errors in the nucleus accumbens in placebo, which was, how-
ever, unaffected by dopaminergic drug treatment.
In OCD, during placebo, the anterior cingulate representa-
tion of negative prediction error (prediction error during omit-
ted rewards) was significantly greater than in controls. In con-
trols, we did not detect a clear cingulate prediction error signal
during omitted rewards. It is possible that our paradigm was
not sufficiently sensitive to detect a negative prediction error
signal in the control group, although it was clearly sufficiently
sensitive to detect the pronounced signal in OCD. The lack of
clear prediction errors in controls may have resulted from our
procedure containing only 40 reward pair stimuli trials; for
comparison, other prior prediction error fMRI studies have
included larger numbers of potentially rewarding trials, such
as 80 (Murray et al. 2008) or 90 (Pessiglione et al. 2006).
Pronounced anterior cingulate prediction error signals are
Fig. 3 Bar chart showing mean negative reward prediction error contrast
value (± 1 SEM) extracted from the anterior cingulate cortex at the time of
reward omission. A higher contrast value indicates that the BOLD signal
was positively correlated with negative prediction error. OCD patients
were significantly different from controls following placebo, but both
groups behave similarly following amisulpride or pramipexole
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consistent with a recent study reporting stronger fronto-striatal
reward prediction error signals in OCD, also using an fMRI
reinforcement learning paradigm (Hauser et al. 2017).
Furthermore, exaggerated responses to errors are a consistent
finding in OCD, with a number of prior studies showing an
overactivation of frontal responses to error processing in OCD
in both fMRI research (Stern et al. 2011; Ursu et al. 2003) and
EEG error-related negativity studies (Gillan et al. 2017;
Mathews et al. 2012).
One previous study of reward anticipation (not learning)
showed nucleus accumbens dysfunction in OCD (Figee et al.
2011). Here, we report an overactivation in the nucleus ac-
cumbens responses to positive prediction errors in OCD, con-
sistent with prior data showing overactivation in OCD across
error tasks and brain regions (Stern et al. 2011; Ursu et al.
2003) and in line with results from Hauser and colleagues
(Hauser et al. 2017), who showed excessive striatal reward
prediction errors in OCD during reversal learning.
We found no significant correlations between anterior cin-
gulate prediction error signals and a general OCD symptom
score; this lack of association is in accordance with the results
from the only other fMRI study of reward prediction error in
OCD (Hauser et al. 2017). However, we did demonstrate an
association between anterior cingulate negative prediction er-
ror signal with self-perceived Bself-regulation^: driven by as-
sociations with subcomponents of difficulty in triggering be-
havioral change, searching for options, and implementing a
plan. This result may be relevant to much recent data suggest-
ing an impairment of goal-directed behavior in OCD and
highlights the importance of cingulate dysfunction in this im-
pairment (Giele et al. 2016; Gillan and Robbins 2014). Our
data suggest that the self-regulation questionnaire may reflect
underlying anterior cingulate function in OCD. We are not
aware of any clinical trials for OCD that have used this scale
as an outcome measure; however, our results suggest that
including a questionnaire measure of goal-directed behavioral
control, such as the SRQ, might be useful in future
clinical trials of interventions targeting cingulate medi-
ated deficits in OCD.
Although the literature provides consistent evidence
linking error processing to dopaminergic function (Schultz
et al. 1997)—a system apparently impaired in OCD (Denys
et al. 2004; Hesse et al. 2005; Moresco et al. 2007; Olver et al.
2009, 2010; Perani et al. 2008; Sesia et al. 2013; Van Der Wee
et al. 2004)—our study extends prior work by directly show-
ing the effect of dopaminergic modulation on brain prediction
error responses in OCD. Overactivation of the anterior cingu-
late cortex in response to negative reward prediction errors in
OCDwas remediated by amisulpride, the selective D2/3 recep-
tor antagonist, as hypothesized. However, the D2/3 agonist
pramipexole unexpectedly had similar, rather than opposite,
effects.
Nevertheless, previous studies have shown that both drugs
can exert bidirectional effects on reward prediction error–
associated responses. Thus, amisulpride or similar D2/3 recep-
tor antagonists can either enhance (Jocham et al. 2011) or
depress (Abler et al. 2007) reward-related brain activity.
Furthermore, dopamine agonist–like medications have also
been shown to be capable of enhancing (Pessiglione et al.
2006) or attenuating (Bernacer et al. 2013) reward prediction
error–associated responses, with the directionality of the effect
being dependent on the particular task, agonist, and dose
employed. Two obvious accounts of this pattern of effects
are that either (I) both agents in our study reduce prediction
errors by operating at opposite sides of a hypothetical inverted
Fig. 5 Significant correlation between self-regulation and negative
prediction error activation in the anterior cingulate region of interest for
OCD patients (rho = − 0.7, p = 0.002): stronger representation of
prediction error during reward omission related to weaker self-regulation.
SRQ—self-regulation questionnaire
Fig. 4 Bar chart showingmean reward prediction error contrast values (±
1 SEM) extracted from the nucleus accumbens. OCD patients were
significantly different from controls following placebo, but both groups
behave similarly following amisulpride or pramipexole
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U-shaped function that determines the net effect of dopami-
nergic modulation on the computation of prediction error or
(II) actions at inhibitory presynaptic receptors, at the level of
the ventral tegmental area (Grace and Bunney 1983) and/or
via terminal autoreceptors (e.g., (Horst et al. 2019)), may be
implicated for one or other drugs that are opposite in sign to
their postsynaptic effects. As the dosage of amisulpride in our
study is between a high and a low dose, the latter account is
further supported by the finding that low doses of amisulpride
in animal studies are associated with a facilitation of behaviors
dependent on presynaptic dopamine receptor activation,
whereas higher doses were found to decrease behaviors asso-
ciated with postsynaptic receptor activation (Perrault et al.
1997). Such an action can only be assessed by determining
an entire dose-response curve, and it is an obvious limitation
of the present data that this was not feasible in this study of
human participants. In particular, it is possible that the low
dose (0.5 mg) of pramipexole employed in our study may
have resulted primarily in presynaptic effects at presynaptic
D2 autoreceptors which have higher affinity for dopamine
than postsynaptic heteroreceptors (Ford 2014). It is also pos-
sible that the degree to which our study drugs act pre- versus
postsynaptically may depend on dopamine receptor availabil-
ity, presynaptic action being favored when receptor availabil-
ity is low. We note prior evidence of low dopamine receptor
availability in OCD (Denys et al. 2004), which is likely to
contribute to differential drug effects between OCD patients
and controls and is consistent with the observed effects of
these dopaminergic agents. We initially intended to use a
higher dose—1.5 mg daily—the lower end of the target daily
dose in Parkinson’s disease (Constantinescu 2008). However,
in clinical practice, it is advised to titrate up to this dose and
indeed on initial testing, we found that acute administration of
1.5 mg without prior titration was poorly tolerated, necessitat-
ing our decision to use the lower dose of 0.5 mg. There are two
further limitations; the first is that 16 out of the 18 patients
were taking medication for OCD at the time of the study,
though the dopaminergic drug treatment effect was present
in OCD irrespective of SSRI treatment (high vs low dose).
A second possible limitation is the relatively modest sample
sizes. The study may have been underpowered to determine
clear differences for some group comparisons. A retrospective
power analysis however provided reasonable confidence
levels for correctly rejecting the null hypothesis (1-β > 0.7).
In some circumstances, pramipexole impairs behavioral
learning, possibly by disrupting phasic dopaminergic signal-
ing, in reinforcement learning tasks (Nagy et al. 2012;
Pizzagalli et al. 2008), and other learning or decision making
tasks (Haley Gallant et al. 2016). In stimulant-dependent in-
dividuals, pramipexole has also been shown to reduce behav-
ioral perseveration during learning tasks (Ersche et al. 2011), a
behavior frequently found in OCD (Giele et al. 2016; Hauser
et al. 2017; Morris et al. 2017). However, Ersche et al. (2011)
found no evidence for normalization of behavioral persevera-
tion in the same set of OCD patients as used in this study. We
also observed no effects of dopaminergic drugs on our behav-
ioral choice measures of learning in OCD patients or healthy
controls although pramipexole did lengthen response times on
reward trials, possibly consistent with previous findings
reporting a slowing of reward learning after a single dose of
pramipexole (Pizzagalli et al. 2008). In contrast, we did dem-
onstrate that the fMRI reward prediction error signal in the
anterior cingulate cortex was sensitive to dopaminergic ma-
nipulation in OCD, consistent with previous observations in a
similar reinforcement learning task that fMRI measures of
learning may be more sensitive than behavioral indices
(Murray et al. 2010).
Although there have been no randomized controlled clini-
cal effectiveness trials of amisulpride in OCD, meta-analysis
confirms that dopamine receptor antagonists reduce
obsessive-compulsive symptoms in SSRI-refractory OCD
(Dold et al. 2015; Veale et al. 2014). Whilst the addition of a
dopamine receptor antagonist medication is a commonly used
augmentation strategy for patients who do not recover
completely on first-line treatments (Hirschtritt et al. 2017),
the mechanisms through which this leads to clinical improve-
ment are not fully understood. Our data suggest one possible
mechanism—remediation of otherwise excessive anterior cin-
gulate error signaling in OCD that is related to the self-
regulatory impairments we found in these patients. In contrast,
we found no effect of dopaminergic drug treatment on the
enhanced positive reward prediction error signals expressed
in the nucleus accumbens of these OCD patients, which was
not shown however to be related to symptoms in this patient
sample.
There have been no clinical trials of pramipexole for OCD,
although three small clinical trials have shown evidence that
the related drug, dexamphetamine, can be effective in OCD
(Insel et al. 1983; Joffe et al. 1991; Koran et al. 2009). Our
results may prompt consideration of further research into low-
dose D2/3 agonist treatment for OCD, although, here, consid-
erable caution, rigorous risk assessment, and very careful ex-
perimental design are advised given prior reports that
pramipexole may cause or worsen compulsive behaviors in
some people (Kolla et al. 2010). Our data are consistent with
the potential therapeutic actions of partial D2/3 agonists; one
such drug, aripiprazole, has already been shown to be effec-
tive in augmentation in OCD, with some evidence of efficacy
at very low doses (Ercan et al. 2015; Janardhan Reddy et al.
2017; Muscatello et al. 2011; Sayyah et al. 2012; Veale et al.
2014). Additional mechanistic and pragmatic research is war-
ranted to determine which OCD patients are most likely to
benefit from dopaminergic treatment.
In summary, these data extend previous evidence of abnor-
mal processing of errors in the fronto-striatal networks in
OCD, by showing that the heightened sensitivity of anterior
Psychopharmacology
cingulate cortex in OCD can be reduced by dopaminergic
modulation. This study therefore is the first to provide direct
evidence of dopaminergic dysfunction during reward predic-
tion error signaling in OCD.
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